Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 6/20 | 0.35 |
| ▸ | CNR2 | P34972 | 6/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6282340 | 1.00 | HTR6 (0.47) | HTR6CA9LMNASMN1; SMN2PLK1 | |
| SCHEMBL6285141 | 0.90 | HTR6 (0.47) | HTR6CA9LMNASMN1; SMN2PLK1 | |
| SCHEMBL6285147 | 0.90 | HTR6 (0.47) | HTR6CA9LMNASMN1; SMN2PLK1 | |
| SCHEMBL6282010 | 0.86 | PTGDR2 (0.37) | HTR6LMNASMN1; SMN2PLK1CNR1 | |
| SCHEMBL6282008 | 0.86 | PTGDR2 (0.37) | HTR6LMNASMN1; SMN2PLK1CNR1 | |
| SCHEMBL6282759 | 0.86 | HTR6 (0.35) | HTR6CA9LMNASMN1; SMN2PLK1 | |
| SCHEMBL6282762 | 0.86 | HTR6 (0.35) | HTR6CA9LMNASMN1; SMN2PLK1 | |
| SCHEMBL6281786 | 0.85 | HTR6 (0.43) | HTR6CA9LMNASMN1; SMN2PLK1 | |
| SCHEMBL6281788 | 0.85 | HTR6 (0.43) | HTR6CA9LMNASMN1; SMN2PLK1 | |
| SCHEMBL6284744 | 0.83 | HTR3A (0.43) | HTR6LMNASMN1; SMN2PLK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906095-B2 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040002527-A1 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002527-A1 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2A | HTR6 1/4885CA9 4840/4885LMNA 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.